Blair William & Co. IL Sells 76 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Blair William & Co. IL reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,600 shares of the medical research company’s stock after selling 76 shares during the period. Blair William & Co. IL’s holdings in Charles River Laboratories International were worth $295,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. UniSuper Management Pty Ltd raised its holdings in shares of Charles River Laboratories International by 20.7% during the 4th quarter. UniSuper Management Pty Ltd now owns 10,033 shares of the medical research company’s stock worth $1,852,000 after buying an additional 1,724 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Charles River Laboratories International by 0.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 80,744 shares of the medical research company’s stock worth $15,002,000 after acquiring an additional 364 shares in the last quarter. Financial Counselors Inc. lifted its holdings in shares of Charles River Laboratories International by 34.3% in the fourth quarter. Financial Counselors Inc. now owns 35,713 shares of the medical research company’s stock worth $6,593,000 after acquiring an additional 9,121 shares during the last quarter. M.D. Sass LLC lifted its holdings in shares of Charles River Laboratories International by 22.0% in the fourth quarter. M.D. Sass LLC now owns 391,824 shares of the medical research company’s stock worth $72,331,000 after acquiring an additional 70,652 shares during the last quarter. Finally, Zions Bancorporation N.A. boosted its stake in shares of Charles River Laboratories International by 18.7% in the 4th quarter. Zions Bancorporation N.A. now owns 10,121 shares of the medical research company’s stock valued at $1,868,000 after purchasing an additional 1,594 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Down 2.9 %

Shares of NYSE:CRL opened at $136.95 on Friday. The company has a market capitalization of $7.00 billion, a PE ratio of 912.99, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $132.99 and a 1 year high of $258.56. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business has a fifty day moving average price of $162.49 and a two-hundred day moving average price of $180.77.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the previous year, the company earned $2.46 earnings per share. The company’s quarterly revenue was down 1.1% on a year-over-year basis. Analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CRL shares. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their price objective for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price target for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Bank of America reduced their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Barclays dropped their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. reduced their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus price target of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).